ARQL

{"sector":"Healthcare","industry":"Drugs","symbol":"ARQL","company_name":"ArQule, Inc.","exchange":"NASDAQ"}

ARQL Articles

Monday was a breakout day for a few biotech companies. Some made absolutely massive runs, practically doubling and then some. The biotechnology sector is pushing near all-time highs, and a few of...
L Brands, DDR, Sabre Corp., and ArQule posted new 52-week lows on Friday.
Recently, biotech stocks have been getting stung pretty good, and now may be a good time to look at companies with pending catalysts.
Dwight Burdette, via Wikimedia CommonsAre you panicking about a government shutdown or about no debt ceiling deal yet? Apparently that is all the market can think of as Washington, D.C., is yet again...
U.S. equity markets opened slightly lower this morning as data from Europe and Asia combined with a larger than expected U.S. trade deficit to pour cool, if not cold, water on the opening. In Asia,...
ThinkstockArQule Inc. (NASDAQ: ARQL) is about to lose some serious hope for investors. It and Daiichi Sankyo announced that the top-line results of phase 2 trial with tivantinib in colorectal...
The three major U.S. stock indexes opened higher this morning but have had trouble staying above the neutral line since late morning. Early reports that Spain would soon ask for a bailout were...
The stock market is mixed on Tuesday, with the Dow Jones Industrial Average down 0.01%, the Nasdaq up 0.21% and the S&P up 0.51%. Tuesday’s winners include a telecommunications company who is...
We are now just about two weeks away from the king of biotech and pharma events in cancer treatments.  The 2012 annual meeting of the American Society of Clinical Oncology (ASCO) is set to take...
Today’s edition of the BioHealth Business Daily is going to be very cancer-dominated due to the American Society of Clinical Oncology (ASCO) 2010 meeting that started this last weekend.  There are...
We have several big movers on news this morning, and none appear to be based upon earnings.  Stocks on the move are ArQule Inc. (NASDAQ: ARQL), BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX),...
Today’s version of the BioHealth Business Daily seems to be more influenced by outside factors more than big blockbuster news.  Still we have many movers, some on news.  Today’s cast members...
These are the top analyst downgrades and cautious research calls we have seen from Wall Street this Thursday morning: ArQule (ARQL) Cut to Sell at UBS. ASML (ASML) Cut to Neutral at Piper Jaffray....
We have compiled an updated lengthy 2009 American Society of Clinical Oncology, or ASCO, document showing many company cancer data presentations slated to start this weekend.   This is broken down...
We are just about to get the first round of abstracts from companies presenting data at this year’s American Society of Clinical Oncology meeting for 2009.  At BioHealthInvestor.com we compiled a...